Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Lynparza - eviQ / Cancer Institute NSW
Product / population
eviQ protocol 3737, olaparib tablets for advanced, metastatic or recurrent disease as specified in the protocol.
Renal method
Indexed eGFR, mL/min/1.73 m2, as printed in eviQ protocol 3737.
Source revision
Online guidance checked 2026-11-07; section revision not established.
All record notes are retained here, including notes about sources not selected in this review.
Lynparza - product and source limitations
The U.S. label uses CrCl in mL/min. eviQ protocol 3737 uses indexed eGFR and leaves exactly 30 outside its printed bands. Use the renal estimate specified by the selected source.
What to reconcile: The U.S. label uses CrCl in mL/min. eviQ protocol 3737 uses indexed eGFR and leaves exactly 30 outside its printed bands. Use the renal estimate specified by the selected source.
For indexed eGFR 31-50, eviQ gives 200 mg orally twice daily and calls for toxicity monitoring. Above 50 it specifies no renal change. The table identifies limited evidence below 30 and leaves exactly 30 outside its printed bands. Use the protocol's renal measure and confirm borderline values.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
